Abstract

Loss of functional pancreatic β-cell mass leads to type 2 diabetes (T2D), attributable to modified β-cell-dependent adaptive gene expression patterns. SetD7 is a histone methyltransferase enriched in pancreatic islets that mono- and dimethylates histone-3-lysine-4 (H3K4), promoting euchromatin modifications, and also maintains the regulation of key β-cell function and survival genes. However, the transcriptional regulation of this important epigenetic modifier is unresolved. Here we identified the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPARγ) as a major transcriptional regulator of SetD7 and provide evidence for direct binding and functionality of PPARγ in the SetD7 promoter region. Furthermore, constitutive shRNA-mediated PPARγ knockdown in INS-1 β-cells or pancreas-specific PPARγ deletion in mice led to downregulation of SetD7 expression as well as its nuclear enrichment. The relevance of the SetD7-PPARγ interaction in β-cell adaptation was tested in normoglycemic 60% partial pancreatectomy (Px) and hyperglycemic 90% Px rat models. Whereas a synergistic increase in islet PPARγ and SetD7 expression was observed upon glycemic adaptation post-60% Px, in hyperglycemic 90% Px rats, islet PPARγ, and PPARγ targets SetD7 and Pdx1 were downregulated. PPARγ agonist pioglitazone treatment in 90% Px rats partially restored glucose homeostasis and β-cell mass and enhanced expression of SetD7 and Pdx1. Collectively, these data provide evidence that the SetD7-PPARγ interaction serves as an important element of the adaptive β-cell response.

Highlights

  • Type 2 diabetes mellitus (T2D) is a progressive metabolic disorder in which defective β-cell adaptive responses are coupled with insulin resistance and genetic susceptibility to be the main pathological contributors [1,2,3,4,5]

  • The SetD7 PPARγ response element (PPRE) with nuclear extracts (NE) showed a shifted band, and we confirmed peroxisome proliferator-activated receptor-gamma (PPARγ)-specific binding by addition of an anti-PPARγ antibody that resulted in a super-shifted complex (Fig. 1C)

  • The mouse-derived βTC6 cells were used for the chromatin immunoprecipitation assay (ChIP) assay since the ChIP assay primers were designed covering the mouse SetD7 PPRE using the mouse SetD7 promoter sequences (Fig. 1A, the primer pairs are presented in italicized font) Using a PPARγ specific antibody, we pulled down a PPARγ-DNA complex

Read more

Summary

RESEARCH ARTICLE

SetD7 (Set7/9) is a novel target of PPARγ that promotes the adaptive pancreatic β-cell glycemic response. Dhananjay Gupta* From the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA

Edited by John Denu
Results
Discussion
Cell culture and in vitro assays
Luciferase reporter gene assay
Measurements of protein and mRNA expression
Animal studies
Pancreas morphometry and immunofluorescence
Statistical analysis
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.